Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1987 1
1988 1
1989 1
1991 1
1993 1
2003 1
2005 4
2006 1
2007 1
2008 1
2010 1
2011 3
2012 1
2014 1
2016 1
2018 1
2020 1
2021 0
Text availability
Article attribute
Article type
Publication date

Search Results

21 results
Results by year
Filters applied: . Clear all
Page 1
Lactadherin promotes VEGF-dependent neovascularization.
Silvestre JS, Théry C, Hamard G, Boddaert J, Aguilar B, Delcayre A, Houbron C, Tamarat R, Blanc-Brude O, Heeneman S, Clergue M, Duriez M, Merval R, Lévy B, Tedgui A, Amigorena S, Mallat Z. Silvestre JS, et al. Among authors: delcayre a. Nat Med. 2005 May;11(5):499-506. doi: 10.1038/nm1233. Epub 2005 Apr 17. Nat Med. 2005. PMID: 15834428
Elucidating immunologic mechanisms of PROSTVAC cancer immunotherapy.
Mandl SJ, Rountree RB, Dela Cruz TB, Foy SP, Cote JJ, Gordon EJ, Trent E, Delcayre A, Franzusoff A. Mandl SJ, et al. Among authors: delcayre a. J Immunother Cancer. 2014 Oct 14;2(1):34. doi: 10.1186/s40425-014-0034-0. eCollection 2014. J Immunother Cancer. 2014. PMID: 25328681 Free PMC article.
Immunotherapy with MVA-BN®-HER2 induces HER-2-specific Th1 immunity and alters the intratumoral balance of effector and regulatory T cells.
Mandl SJ, Rountree RB, Dalpozzo K, Do L, Lombardo JR, Schoonmaker PL, Dirmeier U, Steigerwald R, Giffon T, Laus R, Delcayre A. Mandl SJ, et al. Among authors: delcayre a. Cancer Immunol Immunother. 2012 Jan;61(1):19-29. doi: 10.1007/s00262-011-1077-4. Epub 2011 Aug 7. Cancer Immunol Immunother. 2012. PMID: 21822917 Free PMC article.
21 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page